Third, beyond affecting the levels and phosphorylation of transcriptional regulators with central roles in prostate cancer growth and progression – AR, MYC, and BRD4 – CDKI-73 would blunt the oncogenic transcriptional programs activated by these factors via reducing pSer2-RNAPII. Here, AR is linked to prostate carcinoma.